Highlighted Facts & Figures

Swissmedic’s strategic objectives, as approved by the Federal Council, apply for a period of 4 years.
(Swiss Therapeutic Products Act TPA, Art. 70)

Some 1100 companies have a licence to manufacture or distribute medicinal products in Switzerland.

The Swissmedic Innovation Office has held 24 Scientific Advice Meetings since January 2023, and the number is increasing.

In 2022, 47 applications for authorisation of medicinal product with a new active substance were submitted. These were authorised within an average of 456 days.

Since 1 January 2023, Swissmedic has introduced the Innovation Office and presented the possibilities for collaborating with researchers and startups at 6 events. A further three are planned by 31 July, and more are on the cards.

As part of development cooperation activities, Swissmedic has held nine regulatory training courses since 2018. A total of 288 people from 65 different countries have taken part.

Swissmedic carried out inspections at 15 hospitals in 2022 to check the reprocessing of medical devices.